Developer docs
API playgroundTry for free, no card

Search company profiles

Anomaly Bio

Full company profile

uuid003qpod

Namestring
Anomaly Bio
Legal namestring
Anomaly Bio
Websiteurl
anomalybio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to function as micro-factories, converting simple sugars into functional bio-based ingredients via advanced fermentation. The company's core technology platform designs and optimizes metabolic pathways in microorganisms to produce high-value molecules targeting three end markets: nutrition, crop protection, and personal care — industries collectively described as multi-billion-dollar global markets exposed to geopolitical and climate-driven supply-chain disruptions. The company positions its on-demand, locally deployable biomanufacturing model (requiring only sugar, water, electricity, and a fermentation tank) as a structural replacement for extraction-based ingredient supply chains that depend on agricultural yields and trade flows.

The company was founded in 2022 by Armaan Dhanda and Samyak Baid, who met as freshmen at the National University of Singapore on S&T and NUSC scholarships respectively. Anomaly Bio's first commercial product is a vegan pet food supplement, developed under Mars Petcare's Next Generation Pet Food Program run with Big Idea Ventures. The business model centers on B2B supply of fermentation-derived ingredients to enterprise buyers across nutrition, crop protection, and personal care, with a stated long-term vision of globally distributed, on-demand ingredient manufacturing. Pricing is not publicly disclosed and is described as negotiated on a per-customer, per-ingredient basis, with planned long-term supply contracts as a recurring revenue stream.

As of the November 2025 pre-seed close, Anomaly Bio has raised US$2.6 million in equity led by Pebblebed Ventures, supplemented by over US$120,000 in non-dilutive awards (MIT Water Food Agriculture Innovation Prize 2025, WTFund Fellowship 2024, Singapore-India Hackathon grant under India's G20 initiatives 2023). The pre-seed capital is being deployed to build a dedicated laboratory and pilot-scale biomanufacturing facility in Singapore and to expand R&D headcount in metabolic engineering. The company remains pre-revenue with a team of 1-10 employees, relying on two co-founders and a strategic angel syndicate including operators from Notion, Solugen, Ecovative, CaratLane, MLB, Netmeds, and Undivided Capital.

Short descriptiontext

Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to produce functional bio-based ingredients via fermentation, serving B2B buyers in nutrition, crop protection, and personal care as a resilient alternative to volatile extraction-based supply chains.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fermentation ingredients, strain engineering, metabolic engineering, bio-based ingredients, pet food supplements
Industry4 codes
PRIMARYAFAJAHAH
Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAKAGAH
Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation)
Agriculture & Food Production/Food Processing & Manufacturing/Plant-Based & Alternative Protein Foods Manufacturing
SECONDARYAFANAKAF
Bioprocessing & Fermentation Manufacturing (Bioreactors, Scale-Up, Toll/CMO)
Agriculture & Food Production/Meat, Poultry & Seafood Processing/Meat Alternatives (Plant-Based and Cultivated)
SECONDARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)
NAICS code2 codes
  • Dog and Cat Food Manufacturing311111
  • Food Manufacturing311
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Bio-Based Ingredients
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Bio-based Ingredient Sales
TypeHardware Sales
Description

Sale of fermentation-derived functional ingredients to B2B customers in the nutrition, crop protection, and personal care industries. Early revenue derived from a vegan pet food supplement. Production leverages the company's own pilot-scale biomanufacturing facilities.

anomalybio.com
2B2B Ingredient Supply Contracts
TypeSubscription Recurring
Description

Long-term supply agreements with enterprise customers for bio-based functional ingredients produced via fermentation, providing a stable alternative to volatile agricultural supply chains.

worldbiomarketinsights.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anomaly Bio engineers microorganisms into micro-factories that convert simple sugars into functional bio-based ingredients through advanced fermentation. Its initial commercial product is a vegan pet food supplement, with broader offerings targeted at nutrition, crop protection, and personal care ingredient buyers. Production uses only sugar, water, electricity, and a fermentation tank, enabling scalable, on-demand, location-independent biomanufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • US$2.6 million pre-seed funding raised, validating investor confidence in the biomanufacturing platform
+1 more record
Product overview1 text field

Anomaly Bio is a biotech company that develops functional bio-based ingredients using advanced fermentation and strain engineering. They engineer microbes into micro-factories that transform simple sugars into functional ingredients for nutrition, crop protection, and personal care applications. Their core technology platform enables scalable, on-demand, and globally resilient biomanufacturing that replaces fragile extraction-based supply chains. The company initially launched a vegan pet food supplement and participates in the Mars Petcare Next Generation Pet Food Program.

Product and service2 records
1Vegan Pet Food Supplement
CategoryPet Nutrition / Functional Ingredients
Description

A vegan pet food supplement developed using Anomaly Bio's engineered microbial fermentation technology, serving as the company's first commercial product and entry point into the pet nutrition vertical.

2Fermentation-Derived Bio-Based Functional Ingredients
CategorySpecialty Bio-Based Ingredients
Description

B2B functional ingredients produced via engineered microbial fermentation, designed to replace extraction-based supply chains for nutrition, crop protection, and personal care buyers using sugar, water, electricity, and a fermentation tank.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Anomaly Bio was accepted into Mars Petcare's Next Generation Pet Food Program prior to its seed raise, providing validation, mentorship, and funding for its vegan pet food supplement product. This program is run by Big Idea Ventures and supports alternative protein and pet nutrition innovation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Both co-founders, Armaan Dhanda and Samyak Baid, met as freshmen at NUS in 2022 on the S&T Scholarship and NUSC International Scholarship respectively. The company received support from NUS as part of its early development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fermentation company producing protein ingredients from CO2 and renewable electricity. Comparable as a fermentation-driven alternative ingredient producer targeting the nutrition and food verticals.

TypeBroad incumbent
Description

Large, publicly traded synthetic biology platform serving diverse end markets including nutrition, agriculture, and personal care. Comparable as a broad code biology-as-foundry platform but at vastly greater scale and capital base.

TypeDirect peer
Description

Fermentation-based protein producer using a proprietary microbe (Fusarium strain) to make nutritional proteins for food and personal care. Comparable fermentation platform with overlapping B2B ingredient customer base in nutrition and personal care.

TypeDirect peer
Description

US-based biotech that uses engineered enzymes and fermentation to produce bio-based chemicals and ingredients. Directly comparable as a precision-fermentation ingredient platform targeting industrial and consumer applications; its CTO (Sean Hunt) is also an Anomaly Bio angel investor.

5Culture Biosciences
TypeDirect peer
Description

Fermentation contract development and manufacturing organization serving synthetic biology companies. Comparable as a fermentation services platform and potential partner/complementor in the precision fermentation ingredient stack.

TypeDirect peer
Description

Australia-based precision fermentation scale-up platform building distributed manufacturing capacity for bio-based products. Comparable as a fermentation infrastructure platform enabling on-demand ingredient production.

TypeDirect peer
Description

Precision fermentation company producing animal-free dairy proteins via engineered microbes. Directly comparable technology stack (microbes as micro-factories, sugar-to-functional-ingredient) and serves overlapping B2B nutrition customers.

TypeDirect peer
Description

Precision fermentation company producing sustainable alternatives to palm oil for personal care and food applications. Directly comparable fermentation platform targeting one of Anomaly Bio's named verticals (personal care).

TypeDirect peer
Description

Formerly Clara Foods, uses precision fermentation to produce animal-free proteins (e.g., egg proteins, whey) for CPG and food brands. Directly comparable fermentation platform serving nutrition and ingredient customers.

TypeDirect peer
Description

Mycelium-based biomaterials company using engineered biology to produce sustainable ingredients and packaging. Comparable as a biology-as-manufacturing platform replacing fragile extraction-based supply chains; its CEO (Eben Bayer) is also an Anomaly Bio angel investor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anomaly Bio

Specialty Bio-Based Ingredientsanomalybio.com

Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to produce functional bio-based ingredients via fermentation, serving B2B buyers in nutrition, crop protection, and personal care as a resilient alternative to volatile extraction-based supply chains.

What Anomaly Bio does

Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to function as micro-factories, converting simple sugars into functional bio-based ingredients via advanced fermentation. The company's core technology platform designs and optimizes metabolic pathways in microorganisms to produce high-value molecules targeting three end markets: nutrition, crop protection, and personal care — industries collectively described as multi-billion-dollar global markets exposed to geopolitical and climate-driven supply-chain disruptions. The company positions its on-demand, locally deployable biomanufacturing model (requiring only sugar, water, electricity, and a fermentation tank) as a structural replacement for extraction-based ingredient supply chains that depend on agricultural yields and trade flows.

The company was founded in 2022 by Armaan Dhanda and Samyak Baid, who met as freshmen at the National University of Singapore on S&T and NUSC scholarships respectively. Anomaly Bio's first commercial product is a vegan pet food supplement, developed under Mars Petcare's Next Generation Pet Food Program run with Big Idea Ventures. The business model centers on B2B supply of fermentation-derived ingredients to enterprise buyers across nutrition, crop protection, and personal care, with a stated long-term vision of globally distributed, on-demand ingredient manufacturing. Pricing is not publicly disclosed and is described as negotiated on a per-customer, per-ingredient basis, with planned long-term supply contracts as a recurring revenue stream.

As of the November 2025 pre-seed close, Anomaly Bio has raised US$2.6 million in equity led by Pebblebed Ventures, supplemented by over US$120,000 in non-dilutive awards (MIT Water Food Agriculture Innovation Prize 2025, WTFund Fellowship 2024, Singapore-India Hackathon grant under India's G20 initiatives 2023). The pre-seed capital is being deployed to build a dedicated laboratory and pilot-scale biomanufacturing facility in Singapore and to expand R&D headcount in metabolic engineering. The company remains pre-revenue with a team of 1-10 employees, relying on two co-founders and a strategic angel syndicate including operators from Notion, Solugen, Ecovative, CaratLane, MLB, Netmeds, and Undivided Capital.

Anomaly Bio firmographics

Firmographics
Name
Anomaly Bio
Legal name
Anomaly Bio
Website
https://anomalybio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to produce functional bio-based ingredients via fermentation, serving B2B buyers in nutrition, crop protection, and personal care as a resilient alternative to volatile extraction-based supply chains.
Ownership category
akta.pro rank

Anomaly Bio industry classification

Industry
Product category
Specialty Bio-Based Ingredients
NAICS
Dog and Cat Food Manufacturing (311111), Food Manufacturing (311)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYAFAJAHAH
Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAKAGAH
Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation)
Agriculture & Food Production/Food Processing & Manufacturing/Plant-Based & Alternative Protein Foods Manufacturing
SECONDARYAFANAKAF
Bioprocessing & Fermentation Manufacturing (Bioreactors, Scale-Up, Toll/CMO)
Agriculture & Food Production/Meat, Poultry & Seafood Processing/Meat Alternatives (Plant-Based and Cultivated)
SECONDARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)

Keywords

  • Fermentation ingredients
  • Strain engineering
  • Metabolic engineering
  • Bio-based ingredients
  • Pet food supplements

Where Anomaly Bio is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Anomaly Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Bio-based Ingredient Sales: Sale of fermentation-derived functional ingredients to B2B customers in the nutrition, crop protection, and personal care industries. Early revenue derived from a vegan pet food supplement. Production leverages the company's own pilot-scale biomanufacturing facilities.
  2. B2B Ingredient Supply Contracts: Long-term supply agreements with enterprise customers for bio-based functional ingredients produced via fermentation, providing a stable alternative to volatile agricultural supply chains.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Anomaly Bio product offering

Product offering

Core offering

Anomaly Bio engineers microorganisms into micro-factories that convert simple sugars into functional bio-based ingredients through advanced fermentation. Its initial commercial product is a vegan pet food supplement, with broader offerings targeted at nutrition, crop protection, and personal care ingredient buyers. Production uses only sugar, water, electricity, and a fermentation tank, enabling scalable, on-demand, location-independent biomanufacturing.

Product overview

Anomaly Bio is a biotech company that develops functional bio-based ingredients using advanced fermentation and strain engineering. They engineer microbes into micro-factories that transform simple sugars into functional ingredients for nutrition, crop protection, and personal care applications. Their core technology platform enables scalable, on-demand, and globally resilient biomanufacturing that replaces fragile extraction-based supply chains. The company initially launched a vegan pet food supplement and participates in the Mars Petcare Next Generation Pet Food Program.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vegan Pet Food Supplement A vegan pet food supplement developed using Anomaly Bio's engineered microbial fermentation technology, serving as the company's first commercial product and entry point into the pet nutrition vertical.
  • Fermentation-Derived Bio-Based Functional Ingredients B2B functional ingredients produced via engineered microbial fermentation, designed to replace extraction-based supply chains for nutrition, crop protection, and personal care buyers using sugar, water, electricity, and a fermentation tank.

Quantifiable outcome

  • US$2.6 million pre-seed funding raised, validating investor confidence in the biomanufacturing platform
  • +1 more outcomes

Companies that use Anomaly Bio

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Anomaly Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Anomaly Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Mars Petcare — Next Generation Pet Food ProgramcoreStrategic or Co-development PartnerAnomaly Bio was accepted into Mars Petcare's Next Generation Pet Food Program prior to its seed raise, providing validation, mentorship, and funding for its vegan pet food supplement product. This program is run by Big Idea Ventures and supports alternative protein and pet nutrition innovation.
  • National University of Singapore (NUS)minorStrategic or Co-development PartnerBoth co-founders, Armaan Dhanda and Samyak Baid, met as freshmen at NUS in 2022 on the S&T Scholarship and NUSC International Scholarship respectively. The company received support from NUS as part of its early development.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Anomaly Bio competitors and assessment

Company assessment

Direct peers

  • Air Protein: Fermentation company producing protein ingredients from CO2 and renewable electricity. Comparable as a fermentation-driven alternative ingredient producer targeting the nutrition and food verticals.
  • Nature's Fynd: Fermentation-based protein producer using a proprietary microbe (Fusarium strain) to make nutritional proteins for food and personal care. Comparable fermentation platform with overlapping B2B ingredient customer base in nutrition and personal care.
  • Solugen: US-based biotech that uses engineered enzymes and fermentation to produce bio-based chemicals and ingredients. Directly comparable as a precision-fermentation ingredient platform targeting industrial and consumer applications; its CTO (Sean Hunt) is also an Anomaly Bio angel investor.
  • Culture Biosciences: Fermentation contract development and manufacturing organization serving synthetic biology companies. Comparable as a fermentation services platform and potential partner/complementor in the precision fermentation ingredient stack.
  • Cauldron: Australia-based precision fermentation scale-up platform building distributed manufacturing capacity for bio-based products. Comparable as a fermentation infrastructure platform enabling on-demand ingredient production.
  • Perfect Day: Precision fermentation company producing animal-free dairy proteins via engineered microbes. Directly comparable technology stack (microbes as micro-factories, sugar-to-functional-ingredient) and serves overlapping B2B nutrition customers.
  • C16 Biosciences: Precision fermentation company producing sustainable alternatives to palm oil for personal care and food applications. Directly comparable fermentation platform targeting one of Anomaly Bio's named verticals (personal care).
  • The EVERY Company: Formerly Clara Foods, uses precision fermentation to produce animal-free proteins (e.g., egg proteins, whey) for CPG and food brands. Directly comparable fermentation platform serving nutrition and ingredient customers.
  • Ecovative: Mycelium-based biomaterials company using engineered biology to produce sustainable ingredients and packaging. Comparable as a biology-as-manufacturing platform replacing fragile extraction-based supply chains; its CEO (Eben Bayer) is also an Anomaly Bio angel investor.

Broad incumbents

  • Ginkgo Bioworks: Large, publicly traded synthetic biology platform serving diverse end markets including nutrition, agriculture, and personal care. Comparable as a broad code biology-as-foundry platform but at vastly greater scale and capital base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Anomaly Bio social profiles

Digital presence

Anomaly Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anomaly Bio leadership team

Management profile

Number of profiles

Profiles2 records

Anomaly Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anomaly Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anomaly Bio

What does Anomaly Bio do?

Anomaly Bio engineers microorganisms into micro-factories that convert simple sugars into functional bio-based ingredients through advanced fermentation. Its initial commercial product is a vegan pet food supplement, with broader offerings targeted at nutrition, crop protection, and personal care ingredient buyers. Production uses only sugar, water, electricity, and a fermentation tank, enabling scalable, on-demand, location-independent biomanufacturing.

Is Anomaly Bio a public or private company?

Anomaly Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Anomaly Bio founded?

Anomaly Bio was founded in 2022. It employs 1 to 10 people.

Where is Anomaly Bio based?

Anomaly Bio is headquartered in Singapore, Singapore, in the Asia region.

How does Anomaly Bio make money?

Two revenue lines are on record. Bio-based Ingredient Sales are the primary driver. The others are B2B Ingredient Supply Contracts.

Who are Anomaly Bio's main competitors?

Direct peers on record are Air Protein, Nature's Fynd, Solugen, Culture Biosciences, Cauldron, Perfect Day, C16 Biosciences, The EVERY Company and Ecovative. Ginkgo Bioworks is listed as a broad incumbent.

Does Anomaly Bio have an API?

No public API is recorded for Anomaly Bio.

What industry is Anomaly Bio in?

Anomaly Bio's product category is Specialty Bio-Based Ingredients. Its primary akta.pro industry code is AFAJAHAH, Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation), with a secondary code of AFAKAGAH, Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation). Its NAICS code is 311111 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaMeet Armaan Dhanda, who left college at 22 to turn microbes into tiny factories, his biotech startup raised $2.6 millionArmaan Dhanda, an Indian entrepreneur, co-founded Anomaly Bio with Samyak Baid, a Singapore-based biotech startup that uses engineered microbes to produce ingredients from simple sugars. The company raised $2.6 million in pre-seed funding in November 2025, led by Pebblebed Ventures. Its first product was a fermentation-derived bulk protein for pet food.HindustantimesIndian founder shares why he quit college at 22 to launch biotech startup in Singapore: 'Just getting started'An Indian founder, Armaan Dhanda, dropped out of college to start a biotech company, Anomaly Bio, in Singapore, raising $2.6 million to engineer microbes for ingredient production. The company initially launched a vegan pet food supplement and was accepted into the Mars Petcare program, gaining significant venture funding.WorldbiomarketinsightsSingapore’s Anomaly Bio secures $2.6M to revolutionize biomanufacturingSingapore-based biotech startup Anomaly Bio secured US$2.6 million in pre-seed funding led by Pebblebed Ventures, with participation from Notion, Solugen, and Ecovative, to establish laboratory and pilot-scale biomanufacturing facilities in Singapore while expanding its R&D team. The company uses engineered microbes as micro-factories to produce bio-based ingredients through fermentation, offering a stable alternative to volatile agricultural supply chains. The funding aligns with Singapore's strategic focus on advanced biomanufacturing as a resilient solution independent of global trade disruptions.Asia Business OutlookAnomaly Bio Raises $2.6M to Boost Biomanufacturing R&DAnomaly Bio, a Singapore-based biotech startup founded at the National University of Singapore, raised US$2.6 million in pre-seed funding led by Pebblebed Ventures, with participation from individual investors. The funding will support establishing laboratory and pilot-scale facilities in Singapore and expanding the R&D team, with the company leveraging ScaleUp Bio's GMP-compliant fermentation infrastructure for precision fermentation. The startup engineers microbes to produce bio-based ingredients for crop protection, nutrition, and personal care industries.e27Anomaly Bio powers raises US$2.6M pre-seed fundingAnomaly Bio, a Singapore-based biotech startup developing bio-based ingredients through advanced fermentation and strain engineering, has raised SGD3.37 million (US$2.6 million) in pre-seed funding led by US-based Pebblebed Ventures, with participation from additional investors. The capital will be used to establish laboratory and pilot-scale facilities in Singapore and expand the R&D team focused on metabolic engineering. The company engineers microbes to convert feedstocks like sugars into high-value molecules, aiming to provide scalable, on-demand production for industries including crop protection, nutrition, and personal care.AnomalybioSingapore’s Anomaly Bio raises US$2.6M to turn microbes into micro-factories for resilient ingredient supply chainsSingapore-based biotech startup Anomaly Bio has raised US$2.6 million in pre-seed funding led by Pebblebed Ventures, with participation from angel investors affiliated with Notion, Solugen, Ecovative, and CaratLane. The company programs microbes to convert sugar into bio-based ingredients for crop protection, nutrition, and personal care, aiming to replace fragile supply chains with scalable, on-demand biomanufacturing. The funding will enable Anomaly Bio to establish its own laboratory and pilot-scale facilities in Singapore while expanding its R&D team in metabolic engineering.TNGlobalSingapore’s Anomaly Bio raises $2.6M in pre-seed funding led by Pebblebed VenturesSingapore-based biotech startup Anomaly Bio has raised $2.6 million in pre-seed funding led by US-based Pebblebed Ventures, with participation from individual investors associated with Notion, Solugen, Ecovative, and CaratLane. The funding will enable the company to establish its own laboratory and pilot-scale facilities in Singapore while expanding its metabolic engineering R&D team. The company uses engineered microbes to convert sugar into bio-based ingredients as an alternative to fragile global supply chains disrupted by geopolitical and environmental shocks.